Blood Pressure Control Among U.S. Adults With Hypertension, Stratified by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use: Evidence From the National Health and Nutrition Examination Survey, 2017-2020
Nadra Elfezzani, Theresa M Mambu, Jemie U Nnanna, Ikenna I Iwu, Blen W Nedassa, Eunice Nathan-Otu, Onize Ekome, Enemuo Idinmachukwu, Nagla A Massud, Azeberoje Osueni · 2026
Read Blood Pressure Control Among U.S. Adults With Hypertension, Stratified by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use: Evidence From the National Health and Nutrition Examination Survey, 2017-2020 by Nadra Elfezzani, Theresa M Mambu, Jemie U Nnanna, Ikenna I Iwu, Blen W Nedassa, Eunice Nathan-Otu, Onize Ekome, Enemuo Idinmachukwu, Nagla A Massud, Azeberoje Osueni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13520756.txt.
Description
Nadra Elfezzani and colleagues compare in 2026 blood pressure control in United States adults with high blood pressure. The split is by use of GLP-1 drugs. Data came from a national health survey for 2017 to early 2020. These drugs now spread for diabetes and weight care.
The study held 4,016 adults with high blood pressure. Only 45 people reported GLP-1 use. Weighted counts put users under one percent of this group at that time. Control meant average pressure below set cut-offs. Small user counts limit strong claims. Readers should keep that caveat in mind through all result tables.
Catalog record
| CREATOR | Nadra Elfezzani, Theresa M Mambu, Jemie U Nnanna, Ikenna I Iwu, Blen W Nedassa, Eunice Nathan-Otu, Onize Ekome, Enemuo Idinmachukwu, Nagla A Massud, Azeberoje Osueni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |